Lisata Therapeutics (LTS:0HS8) FCF Margin % : -452.80% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Lisata Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lisata Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-4.53 Mil. Lisata Therapeutics's Revenue for the three months ended in Dec. 2024 was $1.00 Mil. Therefore, Lisata Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -452.80%.

As of today, Lisata Therapeutics's current FCF Yield % is -95.55%.

The historical rank and industry rank for Lisata Therapeutics's FCF Margin % or its related term are showing as below:

LTS:0HS8' s FCF Margin % Range Over the Past 10 Years
Min: -1935.6 Med: -1062.17 Max: -188.74
Current: -1935.6

During the past 13 years, the highest FCF Margin % of Lisata Therapeutics was -188.74%. The lowest was -1935.60%. And the median was -1062.17%.

LTS:0HS8's FCF Margin % is ranked worse than
83.17% of 1016 companies
in the Biotechnology industry
Industry Median: -140.87 vs LTS:0HS8: -1935.60

Lisata Therapeutics FCF Margin % Historical Data

The historical data trend for Lisata Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics FCF Margin % Chart

Lisata Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-1,935.60

Lisata Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-452.80

Competitive Comparison of Lisata Therapeutics's FCF Margin %

For the Biotechnology subindustry, Lisata Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lisata Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Lisata Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lisata Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-19.356	/	1
	=	-1,935.60 %

Lisata Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-4.528	/	1
	=	-452.80 %

Lisata Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (LTS:0HS8) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LSTA:USA

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Lisata Therapeutics Headlines

No Headlines